Bend Biomedical has four primary disease targets for mass drug administration: lymphatic filariasis, onchocerciasis, soil-transmitted helminths (ascariasis, trichuriasis, and hookworm infection), and vitamin A deficiency blindness and related mortality.

Over one billion people are afflicted by one or more of these diseases in the regions of Africa, Central America, South America, the Middle East, South Asia, and Southeast Asia.

Regions affected by Bend Biomedical primary disease targets.

Our medicines will also treat or prevent additional diseases as extended targets, including tropical pulmonary eosinophilia, scabies, strongyloidiasis, mansonelliasis, malaria transmission, oesophagostomiasis, respiratory disease, and other infections.